Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

lts of operations could be adversely affected. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2008, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.



                            VIROPHARMA INCORPORATED
                        Selected Financial Information


    Consolidated Statements of          Three months         Twelve months
     Operations:                           ended                ended
                                        December 31,          December 31,
    (in thousands, except per           -----------           -----------
     share data)                       2008      2007       2008       2007
                                       ----      ----       ----       ----

    Revenue:
    Net product sales                $50,020   $47,696   $232,307   $203,770
                                      ------    ------    -------    -------
    Revenue                           50,020    47,696    232,307    203,770
                                      ------    ------    -------    -------
    Costs and Expenses:
    Cost of sales (excluding
     amortization of product rights)   2,110     2,034      8,874      8,934
    Research and development          21,197    12,504     66,280     35,869
    Selling, general and
     administrative                   22,357    12,710     65,424     37,051
    Intangible amortization            5,505     1,401     10,809      6,120
    Impairment of fixed assets
     held for sale                     2,265         -      2,265          -
              
'/>"/>
SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... stimulate microbial activities in soil. These microorganisms generate plant ... in the soil or in the rhizosphere. The demand ... reducing environmental pollution and on reducing the usage of ... bio fertilizers market with analysis and forecasting of the ...
(Date:1/22/2015)... January 22, 2015 Shimadzu Scientific ... UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength scanning from ... is ideal for applications in a variety of ... , The user-friendly UV-1280 enables intuitive operation, while ...
(Date:1/22/2015)... Mass (PRWEB) January 21, 2015 Cambridge Semantics, ... Web technology, today announced that 2014 was a record-breaking year ... the capabilities of the Anzo Smart Data Platform and our ... and utilize insights from diverse data which led to record ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf ... portfolio of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 ... 5424/5424 R and receive the following:, , ... or Eppendorf Reference 2 ,     3 Free ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... to Battelle for submission of proposals to U.S. ... Corgenix Medical Corporation (OTC Bulletin Board: CONX), a ... has announced a collaboration with Battelle, a Columbus, ... focus includes national security. Under the collaboration, Corgenix ...
... in Treatment of Skin InfectionsNEW HAVEN, Conn., Jan. ... "Company"), a development-stage company focused on the discovery ... of antibiotic-resistant infections, today announced positive final results ... novel fluoroquinolone antibiotic, delafloxacin (RX-3341), in the treatment ...
... Neuralstem, Inc. (NYSE Alternext US: CUR) today announced ... for its patent application, number 10/047,352, for Stable ... and Trade Office (USPTO). This patent covers the ... rendering its growth robust and long-lasting. , (Logo: ...
Cached Biology Technology:Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 2Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 3Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 4Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 5Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent 2Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent 3
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... of green foliage around the globe, observed since the ... part from the increasing concentration of carbon dioxide in ... the globe finds that a carbon dioxide "fertilization effect" ... 2010. Focusing on the southwestern corner of North ...
... countries have joined the International Osteoporosis Foundation (IOF) and ... Conference of Osteoporosis Patient Societies. The conference is ... Paasitorni. Osteoporosis, known as the ,silent, ... easily prone to fracture even after a minor bump ...
... that a simple program that uses pedometers to monitor how ... physical activity, decreasing sitting time, a particular problem for office ... if somebody works out 30 minutes a day, the fact ... time for the rest of the day is in and ...
Cached Biology News:Elevated carbon dioxide making arid regions greener 2Elevated carbon dioxide making arid regions greener 3IOF Worldwide Conference of Osteoporosis Patient Societies opens in Helsinki 2Study: Pedometer program helps motivate participants to sit less, move more 2
... Fixed clamp trays and ... Magnetic drive ... 25 mm amplitude ... ml to 2000 ml, including Fernbach ...
... The MONOLIGHT 3096 Microplate Luminometer ... chemi- and bioluminescence and for,all measurements ... microplates,i.e. for reactions where the light ... of time, as well as for ...
... This kit allows for rapid, convenient, ... The simple bind/wash/elute process utilizes a spin ... uses beads for concentration of proteins which ... beads are strong ion exchangers, offering high ...
... results sooner and save hours of valuable research ... need for a membrane transfer step and western ... No reagents to prepare or mix or dilute ... a simple to perform, mistake-free detection protocol. ...
Biology Products: